Tellgen Corp (300642) - Total Liabilities
Based on the latest financial reports, Tellgen Corp (300642) has total liabilities worth CN¥539.79 Million CNY (≈ $78.99 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 300642 net asset momentum to track the company's year-over-year net asset growth rate.
Tellgen Corp - Total Liabilities Trend (2012–2025)
This chart illustrates how Tellgen Corp's total liabilities have evolved over time, based on quarterly financial data. See 300642 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Tellgen Corp Competitors by Total Liabilities
The table below lists competitors of Tellgen Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aeluma, Inc
NASDAQ:ALMU
|
USA | $1.77 Million |
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
Turkey | TL16.00 Billion |
|
Prataap Snacks Limited
NSE:DIAMONDYD
|
India | Rs2.21 Billion |
|
Yangzhou Chenhua New Material Co Ltd
SHE:300610
|
China | CN¥459.62 Million |
|
Envipco Holding N.V.
AS:ENVI
|
Netherlands | €55.32 Million |
|
Guangxi Hechi Chemical Co Ltd
SHE:000953
|
China | CN¥100.06 Million |
|
Harbin VITI Electronics Corp
SHG:603023
|
China | CN¥135.24 Million |
|
Imagicaaworld Entertainment Limited
NSE:IMAGICAA
|
India | Rs5.00 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Tellgen Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Tellgen Corp.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tellgen Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tellgen Corp (2012–2025)
The table below shows the annual total liabilities of Tellgen Corp from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥576.38 Million ≈ $84.34 Million |
+149.57% |
| 2024-12-31 | CN¥230.94 Million ≈ $33.79 Million |
+60.33% |
| 2023-12-31 | CN¥144.05 Million ≈ $21.08 Million |
-21.74% |
| 2022-12-31 | CN¥184.07 Million ≈ $26.94 Million |
+79.43% |
| 2021-12-31 | CN¥102.59 Million ≈ $15.01 Million |
-2.48% |
| 2020-12-31 | CN¥105.19 Million ≈ $15.39 Million |
+35.13% |
| 2019-12-31 | CN¥77.84 Million ≈ $11.39 Million |
-1.07% |
| 2018-12-31 | CN¥78.68 Million ≈ $11.51 Million |
+100.17% |
| 2017-12-31 | CN¥39.31 Million ≈ $5.75 Million |
-24.23% |
| 2016-12-31 | CN¥51.88 Million ≈ $7.59 Million |
+34.84% |
| 2015-12-31 | CN¥38.47 Million ≈ $5.63 Million |
+25.22% |
| 2014-12-31 | CN¥30.72 Million ≈ $4.50 Million |
-6.56% |
| 2013-12-31 | CN¥32.88 Million ≈ $4.81 Million |
+270.61% |
| 2012-12-31 | CN¥8.87 Million ≈ $1.30 Million |
-- |
About Tellgen Corp
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in… Read more